Olema Pharmaceuticals
OLMA
57 hedge funds and large institutions have $1.66B invested in Olema Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
91.05% more ownership
Funds ownership: 0% → 91.05% (+91%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$312M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$176M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$171M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$150M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$101M |
Top Sellers
OLMA Hedge Fund Activity: Q4 2020 in Review
57 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q4 2020, worth a combined $1.66B.
Buyers outnumbered sellers: 57 funds opened new OLMA positions and 0 closed out — a net gain of 57 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $312M.
- 57 institutional investors held Olema Pharmaceuticals (OLMA) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $1.66B of Olema Pharmaceuticals stock for Q4 2020.
- 57 funds opened new Olema Pharmaceuticals positions in Q4 2020 and 0 closed out, a net change of +57 holders.
- The largest Olema Pharmaceuticals buyer in Q4 2020 was BVF Inc, an estimated $312M added.
Based on aggregated 13F filings for Q4 2020.